Inflammatory biomarkers: Breast cancer survival and possible role in COVID-19 associated comorbidity
Cancer Research Conference: American Association for Cancer Research Annual Meeting, ACCR
; 83(7 Supplement), 2023.
Article
in English
| EMBASE | ID: covidwho-20233149
ABSTRACT
It is known that inflammatory cytokines exacerbate the persistence and severity of various disease states. Breast cancer is the most frequently detected cancer among women worldwide and our recent studies suggest that the inflammatory state of breast (BrCa) cancer, a byproduct of elevated cytokine expression, induces epigenetic modifications leading to increased recurrence. Ongoing NCI clinical trial data (ClinicalTrials.gov, CCC19, NCT04354701) indicates that among patients with cancer and COVID-19, the mortality is high, and the most prevalent malignancies are of breast [21%] and prostate [16%] origin. Due to the risk of cytokine storm during SARS-CoV-2 infection, it is crucial to identify potential mechanisms of hyperinflammation in BrCa patients. In this study, we have evaluated the level of copy number alteration (CNA) of different inflammatory cytokines including IL-8, IL-1b, IL6, IL-8, GM-CSF, TNF-alpha and many others using cBioportal platform which includes over sixty-nine thousand tumor samples (n>69,000 from 213 different studies) from over 33 different cancers. We found that IL-8 has the highest level of amplification in different breast cancers subtypes. Besides, we also analyzed serum samples from BrCa patients, both recurrent and non-recurrent, by different proteomics methods to identify serum cytokines involved in prognosis and recurrence. Comparative data analysis between non-recurrent BrCa against recurrent BrCa patients identified several proteins with very high significance, mostly proteins associated with epigenetic pathways including HDAC9 (P = 0.0035), HDAC5 (P = 0.013), and HDAC7 (P = 0.020). Besides, we identified differential expression of several pro-inflammatory cytokines and immune regulators (IL-8, IL-4, IL-18, IL-12p70) that were present only in recurrent BrCa patient serum. Our data indicate that inflammatory processes contribute to epigenetic modifications that ultimately play a critical role in breast cancer recurrence. In terms of COVID-19 associated co-morbidity, the already dysregulated inflammatory state of BrCa patients may increase their susceptibility to cytokine-storm, leading to increased severity of COVID-related complications and increased mortality rate. Specifically, we hypothesize that the identified elevated level of IL-8 in BrCa patients may lead to a higher basal level of inflammation and contribute to the risk of attaining cytokine-storm during SARS-CoV-2 infection, making it a valuable target for future studies.
adult; breast cancer; breast cancer recurrence; cancer patient; cancer prognosis; cancer recurrence; cancer survival; comorbidity; complication; conference abstract; controlled study; coronavirus disease 2019; cytokine storm; data analysis; epigenetic modification; epigenetics; female; gene amplification; gene expression; human; human tissue; hyperinflammation; inflammation; major clinical study; mortality rate; prognosis; protein expression; proteomics; biological marker; cytokine; endogenous compound; granulocyte macrophage colony stimulating factor; histone deacetylase 5; histone deacetylase 7; histone deacetylase 9; interleukin 12p70; interleukin 18; interleukin 1beta; interleukin 4; interleukin 6; interleukin 8; tumor necrosis factor
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Language:
English
Journal:
Cancer Research Conference: American Association for Cancer Research Annual Meeting, ACCR
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS